NASDAQ:IBRX ImmunityBio Q3 2026 Earnings Report $9.75 +0.06 (+0.62%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$9.65 -0.10 (-1.03%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ImmunityBio EPS ResultsActual EPSN/AConsensus EPS -$0.07Beat/MissN/AOne Year Ago EPSN/AImmunityBio Revenue ResultsActual RevenueN/AExpected Revenue$59.23 millionBeat/MissN/AYoY Revenue GrowthN/AImmunityBio Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateFriday, November 6, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile ImmunityBio Earnings HeadlinesImmunityBio (NASDAQ:IBRX) Stock: Insider Barry Simon Sells 25,000 Shares2 hours ago | americanbankingnews.comImmunityBio, Inc. (NASDAQ:IBRX) Stock Has Consensus Target Price of $14.203 hours ago | americanbankingnews.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.October 8 at 1:00 AM | Priority Gold (Ad)ImmunityBio (NASDAQ:IBRX) Stock: Insider Cheryl Cohen Sells 81,056 Shares3 hours ago | americanbankingnews.comIBRX stock logs best week in over 7 months: Retail eyes Anktiva boost from Trump’s cancer panel pickOctober 5 at 2:29 AM | msn.comIBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger BetSeptember 30, 2026 | finance.yahoo.comSee More ImmunityBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email. Email Address About ImmunityBioImmunityBio (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator. In 2024, the U.S. Food and Drug Administration approved ANKTIVA in combination with Bacillus Calmette-Guérin for adults with non-muscle-invasive bladder cancer that is unresponsive to BCG and includes carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating ANKTIVA and other investigational therapies in additional cancer settings. ImmunityBio was founded by physician and entrepreneur Patrick Soon-Shiong and is headquartered in the United States. The company’s research and clinical development activities have included collaborations and trials involving patients in multiple countries. Its leadership has included Soon-Shiong as executive chairman and global chief medical officer, with Richard Adcock serving as president and chief executive officer.View ImmunityBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadTesla's EV Delivery Beat Is In, So What Happens Now?Penguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth Catalyst Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
